Evaluation of the Roche cobas MTB and MTB-RIF/INH for detecting Mycobacterium tuberculosis complex and resistance to isoniazid and rifampicin: A prospective, multicenter diagnostic accuracy study
Authors:
- Chieh-Lung ChenCCChieh-Lung Chen
- Tai-Fen LeeTLTai-Fen Lee
- 1 September 2025
- journal article
- research article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 66 (6) , 107605
Abstract
No abstract availableKeywords
Funding Information
- National Taiwan University Hospital (202311018RINA)
- China Medical University Hospital (CMUH112-REC1-147)
This publication has 22 references indexed in Scilit:
- Accuracy of cobas MTB and MTB-RIF/INH for Detection of Mycobacterium tuberculosis and Drug ResistanceThe Journal of Molecular Diagnostics, 2024
- Surveillance of multidrug-resistant tuberculosis in Taiwan, 2008–2019Journal of Microbiology, Immunology and Infection, 2022
- Clinical evaluation of the cobas® MTB-RIF/INH reagent and the cobas® 6800 for the detection of isoniazid and rifampicin resistanceTuberculosis, 2022
- Performance of the Roche cobas MTB Assay for the Molecular Diagnosis of Pulmonary Tuberculosis in a High HIV Burden SettingThe Journal of Molecular Diagnostics, 2020
- Whole-genome sequencing-based epidemiological analysis of anti-tuberculosis drug resistance genes in Japan in 2007: Application of the Genome Research for Asian Tuberculosis (GReAT) databaseScientific Reports, 2019
- Management of drug-resistant tuberculosisThe Lancet, 2019
- Outbreak of multidrug-resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational studyThe Lancet Infectious Diseases, 2018
- Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy studyThe Lancet Infectious Diseases, 2018
- Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2017
- WHO's new End TB StrategyThe Lancet, 2015